ALPS

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-20.7K ExitQ1 2026 $21k -- $0.7599

News

zacks.comETFs for Investors Seeking Balance Amid Ceasefire Optimismzacks.comJun 12

globenewswire.comAlps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022globenewswire.comJun 9

zacks.comLove the AI Story but Hate the Concentration Risk? Consider ETFszacks.comJun 2

etftrends.comALPS EQL Swaps SPDR ETFs for New VettaFi Indexetftrends.comJun 1

zacks.comTech-Heavy & Anxious? Pick ETFs to Diversify Beyond the AI Betzacks.comMay 20

Trade ALPS

About Alps Group Inc

Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions. The organization is committed to cultivating a just and balanced healthcare system, ensuring broad availability of early detection, disease prevention, and individualized treatment approaches.

CEO: Seng Kong Tham
IPO Date: Oct 31, 2025

Market Data

Open: $0.7045
High: $0.727
Low: $0.66
Volume: 20.5K
Avg Volume: 22.9K
52W High: $2.90
52W Low: $0.562

Valuation

Market Cap: $120M
Enterprise Value: $125M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-1.7M
Revenue: $3.4M
Net Income: $-68M
Cash: $319k
Debt: $962k

Events

EarningsJun 16